Julian Upton

Pharm Exec talks to Mel Formica, Takeda’s Vice President of Global Market Access, about what he sees as the challenges and opportunities in 2017, and how he envisions the industries market access capabilities evolving.

Pharm Exec speaks to ICON's Ramita Tandon about how the UK and European regulators' market access plans for 2017 will affect the industry.

With the push toward value-based heathcare set to accelerate even more in 2017, Takeda’s VP of global market access discusses the evolution of this all-important engine for medical innovation and bottom-line returns.

Pharm Exec speaks with Ramita Tandon, executive vice president, ICON Commercialization & Outcomes, about the potential impact of UK and European regulators’ market access plans for the industry.

“Volume is not a dirty word” was outgoing GSK head Sir Andrew Witty’s key message at last week’s FT Global Pharmaceutical Conference in London.

Pharm Exec sits down with Jeremy Desai, CEO of Apotex, Canada’s largest producer of generic drugs, to discuss the local impact of mounting pricing pressure-and how smaller and independent companies can survive in an era of consolidation and growing competition.

This year’s 19th annual European Health Forum Gastein (Austria) once again attempted to establish unity in the face of EU woes. But are the Gastein region’s “healing powers” on the wane?

President, Global Vaccines, Merck & Co.

The UK's vote to leave the EU was the hot topic - and a source of exasperation - at last week's annual European Health Forum Gastein.

Global Head, Drug Development, and Chief Medical Officer, Novartis

Vice President, Business Technology, Pfizer Inc.

Envigo's new CEO shares with Pharm Exec his vision for the company’s future, the changes he’s seen in the industry, and his thoughts on that thorny subject, Brexit.

LEO Pharma CEO Gitte Aabo talks to PE about issues pertinent to the dermatology therapy area and how LEO's unconventional business model is helping the company achieve its objectives.

Pharma is no stranger to multi-channel marketing, but, according to Novartis's Panos Papakonstantinou, the industry still isn't getting it right.Pharma is no stranger to multi-channel marketing (MCM), but, according to Panos Papakonstantinou, Novartis's Head, Digital Commercial, Europe, the industry still needs to perfect its approach to MCM. Pharm Exec met up with Panos at last week's eyeforpharma Barcelona event to find out what needs to be done. 

Pharm Exec talks value-based healthcare with Professor Bengt Jönsson of the Stockholm School of Economics.

Anti-corruption NGO Transparency International now has pharma in its sights. Pharm Exec speaks to Sophie Peresson, Director of its Pharmaceuticals & Healthcare Program.

February 09, 2016.

Pharm Exec talks to Jane Griffiths, Company Group Chairman, Janssen EMEA, about how the relationship between industry and patients is maturing.

Pharm Exec interviews Subhanu Saxena, CEO of India pharma giant Cipla, who discusses the longtime emerging market champion’s strategic plans to raise its geographic profile and secure the company’s future in the US.

It’s easy to foresee controversy in 2016 as lagging global economic growth and a messy US political slugfest force the pharma industry’s feet to the fire. Can the industry reclaim a semblance of public approval by confronting its pricing demons and focusing on innovation and a fresh, patient-first message?

Julian Upton sits down with Subhanu Saxena for an update on Cipla's plans to leverage its historic visibility as an emerging market champion to the next level of global leadership in biopharma.

In Pharm Exec’s 2013 end-of-year supply chain roundup, we began with a three-word vision of the immediate future that left little room for ambiguity: “Serialization is coming.” With the impending laws regarding “track and trace” promising to alter the way pharmaceuticals are packaged and shipped, we outlined how global pharma was gearing up to deal with the effects of serialization, and how companies needed to review their own internal practices and those of their outsourcing partners, as the need for technology solutions for both sides of the outsourc

Pharm Exec speaks to Physicians Interactive CEO Donald Tramuto to understand about the key trends shaping the future of e-health.

A recent survey of European biopharma companies and board members revealed that 80 percent of firms find access to qualified senior executives to be a challenge, with the toughest spot to fill being the "seasoned CEO".

With the talk shifting (again) to a Greek exit from the Eurozone, what is pharma thinking?

May 11, 2015.

Inspired by TV’s Mad Men, Julian Upton puts himself into a 1960 executive’s shoes to describe the “ethical pharma” industry of half a century ago

Sunshine was a strong feature of this week's CBI’s Global Transparency Reporting Congress in London.

The looming shift to cross-border compliance in Europe puts the spotlight on the evolving role of chief compliance officers.

Research advocate, "cancer warrior" and survivor Jack Whelan talks to Pharm Exec about what pharma how pharma could improve its communication with patients.